Discloseable transaction
Filed with HKEX · Stock code 1244 · · 4 pages · English
The Board hereby announces the details of the extension of a short-term note (the “Note”) entered into by the Group, which constitutes a discloseable transaction under Chapter 14 of the Listing Rules.Unless otherwise stated, all the capitalised terms used herein shall have the same meaning as those adopted in the Annual Report. 1. BACKGROUND On August 14, 2023, 3D Medicines (Hong Kong) Co., Limite
Earlier from 3D Medicines
- 3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
- 3D Medicines Inc Says Zhang Jing Resigns As CFO
- 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
- 3D Medicines Says Envafoimab Granted Orphan Drug Designation
Later from 3D Medicines
- Interim Report 2026
- Change of principal share registrar and transfer office
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow 3D Medicines into a list and get an email when it puts out news.
Follow 3D Medicines